Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K K Flaharty

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmacotherapy|March 1, 1990
Clinical pharmacology of recombinant human erythropoietin (r-HuEPO)K K Flaharty
Clinical Pharmacy|November 1, 1989
Epoetin: human recombinant erythropoietinK K Flaharty, A M Grimm, P H Vlasses
American Journal of Hematology|February 1, 1991
Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrowsE Piroso, A J Erslev, K K Flaharty, et al.
Pharmacotherapy|January 1, 1989
Hepatotoxicity associated with amiodarone therapyK K Flaharty, S L Chase, H M Yaghsezian, et al.
Bone Marrow Transplantation|January 1, 1993
Fanconi's syndrome due to ifosfamideC Beckwith, K K Flaharty, A K Cheung, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1991
Probenecid enhances central nervous system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal fluid effluxR E Galinsky, K K Flaharty, B L Hoesterey, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 30, 2000
Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffersM A Munger, A Ateshkadi, A K Cheung, et al.
Clinical Pharmacology and Therapeutics|May 1, 1990
Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy menK K Flaharty, J Caro, A Erslev, et al.
Journal of the American Society of Nephrology : JASN|March 1, 1992
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administrationA Besarab, K K Flaharty, A J Erslev, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmacotherapy|March 1, 1990
Clinical pharmacology of recombinant human erythropoietin (r-HuEPO)K K Flaharty
Clinical Pharmacy|November 1, 1989
Epoetin: human recombinant erythropoietinK K Flaharty, A M Grimm, P H Vlasses
American Journal of Hematology|February 1, 1991
Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrowsE Piroso, A J Erslev, K K Flaharty, et al.
Pharmacotherapy|January 1, 1989
Hepatotoxicity associated with amiodarone therapyK K Flaharty, S L Chase, H M Yaghsezian, et al.
Bone Marrow Transplantation|January 1, 1993
Fanconi's syndrome due to ifosfamideC Beckwith, K K Flaharty, A K Cheung, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1991
Probenecid enhances central nervous system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal fluid effluxR E Galinsky, K K Flaharty, B L Hoesterey, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 30, 2000
Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffersM A Munger, A Ateshkadi, A K Cheung, et al.
Clinical Pharmacology and Therapeutics|May 1, 1990
Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy menK K Flaharty, J Caro, A Erslev, et al.
Journal of the American Society of Nephrology : JASN|March 1, 1992
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administrationA Besarab, K K Flaharty, A J Erslev, et al.
Pageof 1